Status:
UNKNOWN
An Innovative Smartphone Application for Adverse Event Management During Breast Cancer Adjuvant Chemotherapy
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The aim of this study is to evaluate benefits of the app in breast cancer patients receiving the docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy. The investigators hypothesized that th...
Eligibility Criteria
Inclusion
- pathological diagnosis of invasive breast cancer
- breast surgery within the past 2-8 weeks
- adult female
- must be able to use mobile phones
- speak and write Chinese fluently to sign the informed consent
Exclusion
- severe comorbidity that interferes with outcome evaluation
- insufficient Chinese language skills
- inability to use mobile phones
- cognitive disability to give informed consent
Key Trial Info
Start Date :
March 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 7 2022
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT05258461
Start Date
March 7 2022
End Date
December 7 2022
Last Update
February 28 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.